This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Greg Lazar, Ph.D.
Co-Founder and Chief Technology Officer at Dualitas Therapeutics


Dr. Lazar is Co-Founder and Chief Technology Officer at Dualitas Therapeutics. Prior to joining Dualitas he led research groups at Xencor, Eli Lilly, and Genentech. He received his BS in Molecular & Cell Biology and Chemistry from Penn State, his PhD in Molecular & Cell Biology from the University of California, Berkeley, and was a postdoctoral fellow at the University of Cambridge, UK. Dr. Lazar is an expert in biotherapeutic engineering and drug discovery, and has developed technologies and molecules that have contributed to 3 approved drugs and over 10 candidates across Phase I-III clinical trials. He is an inventor of over 30 patents and has authored over 40 scientific publications in the fields of protein and antibody structure, design, engineering, and therapeutics.

Agenda Sessions

  • Antibody Architectures and Interfaces - Nature’s Guide to Biotherapeutic Engineering